Product NDC: | 0006-0573 |
Proprietary Name: | CRIXIVAN |
Non Proprietary Name: | indinavir sulfate |
Active Ingredient(s): | 400 mg/1 & nbsp; indinavir sulfate |
Administration Route(s): | ORAL |
Dosage Form(s): | CAPSULE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0006-0573 |
Labeler Name: | Merck Sharp & Dohme Corp. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA020685 |
Marketing Category: | NDA |
Start Marketing Date: | 19960313 |
Package NDC: | 0006-0573-62 |
Package Description: | 180 CAPSULE in 1 BOTTLE (0006-0573-62) |
NDC Code | 0006-0573-62 |
Proprietary Name | CRIXIVAN |
Package Description | 180 CAPSULE in 1 BOTTLE (0006-0573-62) |
Product NDC | 0006-0573 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | indinavir sulfate |
Dosage Form Name | CAPSULE |
Route Name | ORAL |
Start Marketing Date | 19960313 |
Marketing Category Name | NDA |
Labeler Name | Merck Sharp & Dohme Corp. |
Substance Name | INDINAVIR SULFATE |
Strength Number | 400 |
Strength Unit | mg/1 |
Pharmaceutical Classes | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC] |